Covered recipient · General Payments record
HODA RAHMANI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$491.59
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $326.17 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $96.70 | 4 |
| PFIZER INC. | $53.15 | 3 |
| Astellas Pharma US Inc | $51.42 | 2 |
| Lilly USA, LLC | $37.97 | 2 |
| ABBVIE INC. | $29.63 | 1 |
| Exact Sciences Corporation | $26.55 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.77 | 1 |
| DEXCOM, INC. | $14.98 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $29.63 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105352448 | CMS |
| Astellas Pharma US Inc | $33.67 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139279046 | CMS |
| Astellas Pharma US Inc | $17.75 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139302790 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.77 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117859989 | CMS |
| Dexcom, Inc. | $14.98 | 11/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153303917 | CMS |
| Exact Sciences Corporation | $13.38 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114845304 | CMS |
| Exact Sciences Corporation | $13.17 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114845310 | CMS |
| Lilly USA, LLC | $20.40 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135026264 | CMS |
| Lilly USA, LLC | $17.57 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135005129 | CMS |
| Novo Nordisk Inc | $23.21 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097514041 | CMS |
| Novo Nordisk Inc | $19.55 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096686144 | CMS |
| Novo Nordisk Inc | $31.92 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097742232 | CMS |
| Novo Nordisk Inc | $22.02 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096597330 | CMS |
| PFIZER INC. | $17.60 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131128953 | CMS |
| PFIZER INC. | $15.75 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131427374 | CMS |
| PFIZER INC. | $19.80 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132100951 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.